Methodologies to Increase the Level of Evidence of Real-life Proton Therapy in Head and Neck Tumors.

head and neck cancer model-based approach proton therapy randomized trials registries

Journal

International journal of particle therapy
ISSN: 2331-5180
Titre abrégé: Int J Part Ther
Pays: United States
ID NLM: 101674108

Informations de publication

Date de publication:
2021
Historique:
received: 31 08 2020
accepted: 12 02 2021
entrez: 21 7 2021
pubmed: 22 7 2021
medline: 22 7 2021
Statut: epublish

Résumé

This review aims to present and assess available and new methodologies to increase the clinical evidence of proton therapy data for patients with head and neck cancer. Despite the increasing number of scientific reports showing the feasibility and effectiveness of proton therapy in head and neck cancer, clinical evidence on the potential benefits of its use remains low for several reasons. In this article, the pros and cons of consolidated and new methodologies in this setting such as randomized clinical trials, the model-based approach, and the use of prospective multicentric registries will be detailed.

Identifiants

pubmed: 34285959
doi: 10.14338/IJPT-20-00051.1
pii: THEIJPT-D-20-00051R1
pmc: PMC8270108
doi:

Types de publication

Journal Article

Langues

eng

Pagination

328-338

Informations de copyright

©Copyright 2021 The Author(s).

Déclaration de conflit d'intérêts

Conflicts of Interest: The authors have no conflicts of interest to disclose.

Références

Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1075-81
pubmed: 18486355
Front Radiat Ther Oncol. 2007;40:94-115
pubmed: 17641504
Radiat Oncol. 2019 Dec 9;14(1):221
pubmed: 31818301
Radiother Oncol. 2012 Oct;105(1):107-14
pubmed: 21907437
Radiother Oncol. 2016 Dec;121(3):381-386
pubmed: 27641784
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):30-41
pubmed: 27325480
Radiother Oncol. 2012 Oct;105(1):94-100
pubmed: 22169766
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1337-49
pubmed: 12128137
Radiother Oncol. 2016 Feb;118(2):286-92
pubmed: 26867969
Radiat Oncol. 2013 May 04;8:113
pubmed: 23641879
J Clin Oncol. 2018 Jun 20;36(18):1813-1822
pubmed: 29293386
Oral Oncol. 2019 Jan;88:66-74
pubmed: 30616799
Radiother Oncol. 2018 Jul;128(1):19-25
pubmed: 29606525
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
Radiother Oncol. 2013 Jun;107(3):267-73
pubmed: 23759662
Lancet Oncol. 2017 Sep;18(9):1221-1237
pubmed: 28757375
Radiother Oncol. 2020 Oct;151:206-213
pubmed: 32768508
Radiother Oncol. 2014 Oct;113(1):95-101
pubmed: 25443500
Clin Med (Lond). 2008 Dec;8(6):579-88
pubmed: 19149278
EClinicalMedicine. 2020 Jan 31;20:100269
pubmed: 32300733
Brachytherapy. 2021 Jan-Feb;20(1):44-49
pubmed: 32826171
Radiother Oncol. 2013 Oct;109(1):159-64
pubmed: 23993399
Lancet Oncol. 2011 Feb;12(2):127-36
pubmed: 21236730
Head Neck. 2016 Apr;38 Suppl 1:E1886-95
pubmed: 26705956
J Thorac Dis. 2018 Apr;10(Suppl 9):S1124-S1126
pubmed: 29849206
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):344-352
pubmed: 26454680
Radiother Oncol. 2016 Jul;120(1):48-55
pubmed: 27342249
Biomed J. 2015 Sep-Oct;38(5):391-8
pubmed: 25768324
N Engl J Med. 2016 Feb 11;374(6):504-6
pubmed: 26863351
N Engl J Med. 2000 Jun 22;342(25):1887-92
pubmed: 10861325
J Clin Oncol. 2020 May 10;38(14):1569-1579
pubmed: 32160096
Lancet Oncol. 2011 Sep;12(10):933-80
pubmed: 21958503
Radiother Oncol. 2019 Aug;137:130-136
pubmed: 31100606
Lancet Oncol. 2014 Aug;15(9):1027-38
pubmed: 24980873
J Clin Oncol. 2008 Jan 10;26(2):175-6
pubmed: 18182658
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):363-73
pubmed: 15925451
J Appl Clin Med Phys. 2020 Sep;21(9):155-162
pubmed: 32715634
Radiother Oncol. 1991 Mar;20(3):166-76
pubmed: 1852908
Eur J Cancer. 2020 Apr;129:41-49
pubmed: 32120274
Clin Oncol (R Coll Radiol). 2020 Feb;32(2):84-88
pubmed: 31604604
Radiother Oncol. 2016 Feb;118(2):281-5
pubmed: 26924342
Pract Radiat Oncol. 2019 Nov;9(6):395-401
pubmed: 31445187
Clin Oncol (R Coll Radiol). 2003 Feb;15(1):S37-50
pubmed: 12602563
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Lancet Oncol. 2020 Jan;21(1):e18-e28
pubmed: 31908301
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):981-91
pubmed: 17145528

Auteurs

Francesco Dionisi (F)

Proton Therapy Unit, Department of Oncology, Azienda Provinciale per I Servizi Sanitari (APSS), Trento, Italy.
Department of Radiation Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.

Lamberto Widesott (L)

Proton Therapy Unit, Department of Oncology, Azienda Provinciale per I Servizi Sanitari (APSS), Trento, Italy.

Marco Van Vulpen (M)

Proton Therapy Center, Delft, the Netherlands.

Clifton David Fuller (CD)

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Rocco Frondizi (R)

Department of Management and Law, Tor Vergata University of Rome, Rome, Italy.

Marco Meneguzzo (M)

Department of Management and Law, Tor Vergata University of Rome, Rome, Italy.
Centre for Organisational Research, Health and Public Management, Università della Svizzera Italiana (USI), Lugano, Switzerland.

Pierre Blanchard (P)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Maurizio Amichetti (M)

Proton Therapy Unit, Department of Oncology, Azienda Provinciale per I Servizi Sanitari (APSS), Trento, Italy.

Giuseppe Sanguineti (G)

Department of Radiation Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Regina Elena National Cancer Institute, Rome, Italy.

Classifications MeSH